MedTrace Logo

Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children

NCT04275284 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-08-23

No results posted yet for this study

Summary

This study will evaluate the persistence of immunogenicity following a reduced dosing schedule of 10- or 13-valent Pneumococcal Conjugate Vaccine (PCV10, PCV13). This is the follow-up of a randomized controlled trial in which children received a single priming dose of PCV10 or PCV13 (at 6 or 14 weeks of age) followed by booster dose at 9 months of age (1+1 schedule), compared to a 2+1 PCV schedule (6, 14 weeks of age and 9 months of age).

Conditions

Interventions

BIOLOGICAL

PCV10

0.5 ml injection

BIOLOGICAL

PCV13

0.5 ml injection

Sponsors & Collaborators

  • University of Witwatersrand, South Africa

    lead OTHER

Principal Investigators

  • Shabir A Madhi, MD PhD · University of the Witwatersrand, South Africa

Eligibility

Min Age
3 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-14
Primary Completion
2022-12-01
Completion
2022-12-01

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04275284 on ClinicalTrials.gov